Amwell Announces New Chief Marketing Officer Susan Worthy


BOSTON–(BUSINESS WIRE)–Amwell® (NYSE:AMWL), a national leader in telehealth, today announced that Susan Worthy has joined the company as Chief Marketing Officer. Susan is a permanent marketing executive with over 25 years of experience leading marketing for healthcare services and technology companies. In her new role, Susan will be responsible for leading Amwell’s global marketing strategy and will play a central role in strengthening the company’s market position to drive continued growth, as well as shareholder and customer value. .

“We are thrilled to have Susan join our leadership team. Her impressive experience combined with her creativity, data-driven approach and proven track record of working with and leading marketing strategy for market-leading companies, clearly showed that she was the right person to further enhance our differentiation. in the market, our cross-functional approach. bring strategies to market and serve as a strategic partner,” said Brendan O’Grady, director of growth and commerce, Amwell. “As we continue to go through a period of great transformation for Amwell and for our industry, I am confident that Susan will have an immediate impact on our team and our ability to serve current and future customers.”

Susan joins Amwell from Optum, where she has spent the past six years leading marketing teams, driving product value, and establishing thought leadership and market awareness to achieve growth and shareholder value. Prior to Optum, Susan was Head of Marketing for Aetna and Best Doctors (now Teladoc) as well as several other healthcare companies. Susan has a passion for brand storytelling and is highly regarded for her dynamic leadership and ability to build and motivate results-driven teams.

“Amwell has a long history of improving healthcare availability through the use of technologies that result in better clinical and financial outcomes,” Worthy said. access, care coordination, patient experience and behavioral health support. I look forward to helping Amwell bring this story of differentiation and excellence to market and contributing to the company’s mission and journey. »

Susan succeeds Mary Modahl, who is retiring on April 30, having helped ensure a smooth transition.

“Mary has been a trusted partner throughout her 10+ years at Amwell. She was instrumental in shaping Amwell’s go-to-market strategy and organizational culture during our early phase of growth. Our Board of Directors and entire management team thank Mary for her contributions and wish her well as she enters this new chapter,” O’Grady continued.

About Amwell

Amwell is a leading telehealth platform in the United States and around the world, connecting and enabling providers, insurers, patients and innovators to deliver better access to more affordable, higher quality care. Amwell believes digital care delivery will transform healthcare. The company offers a single, comprehensive platform to meet all telehealth needs, from urgent care to acute and post-acute care, as well as chronic care management and healthy living. With more than a decade of experience, Amwell provides telehealth solutions to more than 2,000 hospitals and 55 health plan partners with more than 36,000 employers, spanning more than 80 million lives. For more information, please visit

American Well, Amwell, Converge, SilverCloud, Conversa and Carepoint are either registered trademarks or trademarks of American Well Corporation in the United States and other countries. All other trademarks used herein are the property of their respective owners.

Forward-looking statements

This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations, financial condition, business strategy and management plans and objectives for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “predict”, “project”, “should”, “will” or “would”, or the negative of these words or other similar terms or expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our beliefs and assumptions only as of the date of this release. These statements, and the associated risks, uncertainties, factors and assumptions, include, but are not limited to: low growth and increased volatility in the telehealth market; inability to adapt to rapid technological changes; increased competition from existing and potential new participants in the healthcare industry; changes in healthcare laws, regulations or trends and our ability to operate in the highly regulated healthcare industry; our ability to comply with federal and state privacy regulations; the significant liability that could result from a cybersecurity breach; and other factors described under “Risk Factors” in our Form 10-K filed with the SEC on March 26, 2021. These risks are not exhaustive. Except as required by law, we undertake no obligation to update these forward-looking statements or to update why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information about factors that could cause actual results to differ materially from those anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission. These materials, when available, are available in the Investor Relations section of our website at and on the SEC’s website at


Comments are closed.